Lycopodium

Selected form

-

Method of action: Adaptogenic, Adrenolytic, Adsorbing, Alpha-Adrenomimetic, Ample Deficiency, Analgesic, Analgetic, Androgenic, Angioprotective, Anorexigenic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lycopodium

Understanding Lycopodium

Lycopodium clavatum, commonly known as stag's horn moss or ground pine, is a species of clubmoss belonging to the Lycopodiaceae family. Despite its common names, it is not a true moss but a spore-bearing vascular plant. It is characterized by its prostrate stems that creep along the ground, sending up erect, branched stems covered in small, scale-like leaves.

Origin and Preparation

The plant is native to many temperate and subarctic regions across the Northern Hemisphere, often found in heaths, moors, and acidic woodland soils. The primary part used in therapeutic contexts is the fine, pale yellow powder composed of the dried spores.

In its raw state, the spores are highly hydrophobic and difficult for the body to digest. To prepare Lycopodium for medicinal use, the spores undergo a specific process of trituration or rhythmic succussion. This process breaks down the hard outer coating of the spores, intended to release the internal biological constituents.

Historical Context

Lycopodium has a long history of traditional use. Historically, the dry spores were frequently used in pharmacies as a dusting powder to prevent pills from sticking together and to coat sensitive skin areas. Because the powder is highly flammable due to its high oil content, it was also once used in early photography and theatrical performances to create flashes of light or artificial lightning.

Therapeutic Principles

Within traditional and alternative health frameworks, Lycopodium is often associated with the management of digestive and metabolic functions. It is typically considered for individuals who present with a specific constitutional profile, which may include a tendency toward slow digestion or feelings of abdominal discomfort.

In these practices, the focus is not merely on the physical symptoms but on the overall pattern of the individual’s health. Practitioners look for a cluster of characteristics when determining if Lycopodium is the appropriate choice, focusing on the timing of symptoms and the general temperament of the patient.

Regulatory References

DailyMed Label for Lycopodium clavatum

What side effects are possible with Lycopodium?

The official safety documentation for Lycopodium clavatum products, typically marketed as unapproved homeopathic preparations, does not contain a conventional, clinically validated safety profile. Government regulatory agencies, such as the U.S. Food and Drug Administration (FDA), have explicitly stated that these products have not been evaluated for safety or efficacy, meaning that standard lists of adverse drug reactions (ADRs) are not included in the labeling.

Official Regulatory Safety Constraints

Due to this regulatory status, the labels do not utilize standard pharmacovigilance terminology. There are no official classifications of side effects by frequency (such as common, uncommon, or rare) or by System-Organ Class (such as gastrointestinal or neurological). Additionally, the labels do not document specific serious adverse reactions.

Population-Specific and General Precautions

Safety warnings documented in the official labeling specifically address certain patient populations. Individuals who are pregnant or breast-feeding are constrained by the official safety notes, which require them to consult a health professional before using the product.

General regulatory requirements also mandate that the product must be kept out of the reach of children. Furthermore, in line with requirements for all oral preparations, the official safety text advises that medical attention should be sought immediately in the event of accidental overdose. Some liquid preparations contain alcohol, and solid forms contain lactose or sucrose, which may be considerations for specific users.

Overdose and Emergency Response

Lycopodium Overdose and when to seek help

The official regulatory profile for Lycopodium, a substance derived from Lycopodium clavatum spores and prepared in a highly diluted form, is primarily defined by the absence of specific toxicological data and the presence of mandatory emergency actions.

Documented Overdose Manifestations

Official labeling from government health authorities does not document expected symptoms, clinical signs, or laboratory abnormalities resulting from an overdose of this highly diluted preparation. Consequently, the documentation is also devoid of information regarding severe or life-threatening outcomes, and it does not define a toxic dose level, list specific monitoring requirements, or detail population-specific overdose considerations in the context of increased severity. No specific antidotes or supportive management measures are described in the official warnings section.

Mandatory Emergency Actions

The regulatory framework mandates explicit, non-optional actions in the event of accidental ingestion or overdose. The official label explicitly states the required protocol: in the case of overdose, individuals must get medical help or contact a Poison Control Center right away. This instruction applies to all instances of actual or suspected overdose. The required action confirms that the regulatory guidance emphasizes immediate external medical professional contact as the sole documented course of action.

Therapeutic Uses of Lycopodium

What Lycopodium Treats: Main Uses and Benefits

This section outlines the primary symptomatic domains where Lycopodium is commonly used to provide supportive therapeutic benefit and symptomatic relief. Its traditional use is applied in addressing certain distressing symptoms, such as those related to digestive complaints. This application is centered on the management of specific symptom patterns.

Lycopodium is relevant in clinical settings that involve acute or unstable symptom patterns, and is used in domains where short-term symptom management is appropriate, particularly symptoms linked to organ-specific functional stress (such as in the abdomen) or symptoms associated with acute or episodic changes (such as general discomfort).

It helps address symptom clusters that may become intense or disruptive, and is commonly used when short-term symptomatic assistance is needed. This supportive relief contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

Quick Fact: Supports Symptom Management during Episodic Discomfort

Regulatory References

U.S. National Library of Medicine DailyMed listing

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Lycopodium — Official Regulatory Information

The eligibility profile for Lycopodium products, which are regulated as unapproved homeopathic over-the-counter drugs in the U.S., is defined by conditional warnings rather than formal, disease-based contraindications. The official labeling establishes specific limitations for use in certain age groups and physiological states.

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and children aged 12 years and older are generally included under standard labeled conditions.
Populations for whom use is contraindicated	No absolute medical contraindications based on specific disease states or organ function (e.g., hepatic or renal impairment) are explicitly listed in official labeling.
Pregnancy and lactation eligibility	Conditional Use Only: If pregnant or breast-feeding, individuals are explicitly directed by the label to ask a health professional before use.
Age-related eligibility rules	Use in children under 12 years or infants below 2 years is restricted and requires mandatory consultation with a physician or health professional.

These official statements define who can or cannot use the medicine by establishing clear conditional restrictions tied to vulnerable populations (pregnancy, lactation) and mandatory consultation requirements for young children. All other adult populations are generally permitted to use the medicine under the standard labeled conditions.

What should I know about interactions with other medicines?

The official regulatory profile for Lycopodium, which is classified as a highly diluted botanical preparation, is characterized by the absence of specific interaction study data in government-mandated labeling. Prescribing information published by authorities, such as the U.S. National Library of Medicine DailyMed, does not contain the standard components of a comprehensive interaction section.

Interaction Profile Summary

Interaction Type	Official Regulatory Finding
Drug-Drug & Metabolic	No specific medicines are listed as formally contraindicated, and there are no documented reports of CYP enzyme or drug transporter interactions.
Pharmacodynamic & Exposure	Official regulatory documents do not describe pharmacodynamic effects or alterations to the plasma concentrations (AUC/Cmax) of co-administered substances.
Alcohol / Supplements	No formal interaction outcomes are documented for use with alcohol, supplements, or herbal products.

The only interaction-related constraint noted in some official labeling is a procedural requirement for administration timing separation relative to food intake. This constraint mandates that the medicine must be administered separated from meals by a specific duration. This profile structure confirms that the official regulatory interaction map for Lycopodium is defined by the absence of conventional pharmacological data regarding metabolic or exposure-altering effects, and no population-specific interaction considerations are documented.

Mechanism of Action

The mechanism of action for the active constituents of Lycopodium clavatum focuses on influencing cellular regulatory and protective processes, though the conventional molecular mechanism for the highly diluted preparation is generally not fully verified. The primary action involves the inhibition and downregulation of major cellular signaling hubs. This includes acting on the NF-κB pathway and enzymes like COX-2 and iNOS. This modifies molecular steps that reduce the production of key inflammatory mediators, contributing to a reduction in the expression of inflammatory mediators. Concurrently, the constituents modulate intrinsic antioxidant mechanisms against cellular damage by scavenging free radicals and restoring endogenous antioxidant enzymes such as Superoxide Dismutase. This engages mechanisms that reduce oxidative stress, resulting in an altered state of physiological response. Furthermore, the active components influence metabolic and neuro-enzyme activity, interfering with enzymes like Prolyl Endopeptidase (PEP) to affect biochemical balance relevant to systemic regulatory mechanisms.

Dosage and Administration Information

Official Instructions for Lycopodium Administration

Administration of Lycopodium is governed by specific instructions provided for highly diluted products. These rules dictate the route, dosage, frequency, and time limit for use, focusing strictly on the procedural aspects of intake.

Administration Scope and Dosage

Entity	Instruction According to Labeling
Route of Administration	Primarily Oral or Sublingual (dissolving under the tongue).
Standard Adult Dose	Typically 3 to 6 units (pellets, drops, or tablets) per administration, varying by specific formulation.
Dosing Frequency	Administration is generally performed three times daily or 3–4 times per day, initiated at the onset of symptoms.
Time of Intake	While often taken before or after meals, some forms specify that the dose should not be taken within 15 to 30 minutes of consuming food or drink.

Procedural and Population Rules

Entity	Instruction According to Labeling
Preparation	Liquid forms may require dilution in water. Solid forms (pellets, tablets) are typically dissolved in the mouth or under the tongue.
Duration of Use	Use is limited to short-term, self-limiting conditions. Discontinue and seek assistance if symptoms do not improve within a defined period, generally 3 to 7 days.
Pediatric Use	For children age 2 and older, the dose is typically one-half the adult dose or a specific lower pellet count. For children under age 2, a healthcare provider must be consulted before use.

The usage protocol is defined as a multiple-times-daily oral regimen intended for temporary support. These explicit, label-based instructions establish the required technique, frequency, and maximum duration of use.

Recent Clinical Evidence

Research evidence / Overview of studies for Lycopodium

Evidence for Digestive and Gastrointestinal Conditions

Research has explored Lycopodium in studies exploring symptoms associated with Irritable Bowel Syndrome (IBS) and acute childhood diarrhea. The evidence includes Randomized Controlled Trials (RCTs) and systematic reviews exploring symptoms. The studies focused on patient-reported outcomes describing perceived discomfort, monitoring measures such as overall symptom severity scores, and the duration and frequency of acute symptoms.

Findings describe patterns observed in the observed populations, where research describes changes measured during the study period. Systematic reviews note that the evidence level is categorized as low to moderate. Many of the studies conducted have relied on small sample sizes (modest N), and the durability of any observed symptomatic changes in chronic conditions is not fully established.

Evidence for Metabolic and Liver Support

Research has explored Lycopodium in studies related to metabolic function and the liver, such as Non-Alcoholic Fatty Liver Disease (NAFLD) and certain cases of jaundice in children. The available evidence is primarily derived from descriptive Case Series, Clinical Observational studies, and initial single-arm trials, which means they did not include a control group for comparison.

These research settings examined systemic or functional imbalance by monitoring liver function biomarkers and measuring patient-reported outcomes. The research is limited by single-center or single-arm studies. Data for these groups remain insufficient, and generalizability is uncertain.

What is Still Uncertain About Lycopodium

Long-term effects are not fully established, as most research explores short-term symptom changes. Comparative evidence is lacking in many areas. Furthermore, the findings were mixed across some controlled studies, meaning the data show patterns related to patient-reported experiences, but the certainty remains low for objective, definitive outcomes. Further robust, large-scale controlled trials would contribute to the existing evidence landscape.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Lycopodium (FAQ)

Q: What are the known common side effects listed in the official drug information?

According to the official regulatory profile for this type of highly diluted preparation, there are generally no standard lists of common, uncommon, or rare side effects documented. The U.S. Food and Drug Administration (FDA) indicates that these products have not been formally evaluated for safety or efficacy. Therefore, a conventional side-effect profile is not included in the official labeling.

Q: Is Lycopodium safe to use long-term?

Official instructions specify that Lycopodium preparations are intended for short-term use only, typically for conditions that resolve quickly. The official guidance is to discontinue use and seek assistance if symptoms do not improve within a defined period, such as 3 to 7 days. Research literature indicates that long-term effects for this preparation are not fully established.

Q: Is it okay to have coffee or alcohol while using Lycopodium?

Official regulatory documents do not list formal interaction outcomes with alcohol or coffee. However, some liquid Lycopodium preparations contain alcohol as an inactive ingredient, which may be a consideration for some users. The only constraint noted in some official labeling is a procedural requirement to separate the time of intake from food or drink.

Q: Is Lycopodium a prescription-only medicine?

In the U.S., this preparation is typically classified as a Human Over-the-Counter (OTC) Drug. It is generally marketed as an unapproved homeopathic product and can be purchased without a prescription.

Q: Does Lycopodium affect birth control pills?

Official regulatory documents, such as those published by the FDA's DailyMed, do not contain documented reports of drug-drug interactions with other medicines, including oral contraceptives. The interaction profile is generally defined by the absence of conventional pharmacological data.

Q: What is the average duration of treatment with Lycopodium?

The administration instructions limit the use of this product to a maximum of 3 to 7 days for self-limiting symptoms. This duration is established in the regulatory labeling as the maximum time to use the product before seeking a health professional if the condition does not improve.

Q: Can Lycopodium be used by people with kidney issues?

Official labeling does not explicitly list specific organ impairments, such as kidney (renal) or liver (hepatic) issues, as formal medical contraindications for use. Official constraints are explicitly tied to vulnerable populations, such as infants, pregnant individuals, and those who are breastfeeding.

Q: What is the difference between Lycopodium and Lycopodium clavatum?

Lycopodium clavatum is the scientific name for the clubmoss plant, which is the botanical source of the medicine. Lycopodium (the drug) is the final, highly processed pharmaceutical product generally made from the spores of the Lycopodium clavatum plant.

Q: Is it safe to take herbal remedies with Lycopodium?

Official regulatory documents related to this preparation do not describe formal interaction outcomes for use with herbal products or dietary supplements. The drug's official interaction profile typically lacks conventional pharmacological data regarding metabolic or exposure-altering effects.

Q: How is Lycopodium legally classified (e.g., OTC vs. prescription)?

In the U.S. and other regions, this preparation is classified as an Over-the-Counter (OTC) Drug. It falls under the category of highly diluted, unapproved homeopathic medicines and is therefore available without a prescription.

Q: How to Store and Dispose of Lycopodium?

Consumer forms of the medication should be stored in a manner that is out of the reach of children, with the container tightly closed. When disposing of the product, official instructions mandate that disposal must follow national and local regulations, and the waste should not be allowed to enter drains or waterways.

Q: Does Lycopodium interact with common pain relievers like ibuprofen?

The official regulatory interaction profile is defined by the absence of conventional pharmacological data. This means that official documents do not list specific medicines, like common pain relievers such as ibuprofen, as formally contraindicated due to drug-drug interactions.

Q: Are there any specific food types that interact with Lycopodium?

The official interaction profile does not document specific food types that have a known pharmacological interaction with the drug substance. The primary food-related constraint noted is a procedural requirement to separate the timing of administration from meals.

Q: Is Lycopodium suitable for use in elderly patients?

Official labeling generally includes all adults and patients 12 years and older under standard labeled conditions for use. The regulations do not list specific age-related constraints or consultation requirements that are mandatory for the elderly population. Standard labeled conditions generally apply to adults 12 years and older.

Q: What are the ingredients in Lycopodium besides the main drug substance?

The official inactive ingredient section of product labels specifies that ingredients can vary by formulation. Solid forms (pellets or tablets) often contain substances like lactose or sucrose, while some liquid preparations may contain alcohol.

Q: Are there any known severe adverse reactions to Lycopodium?

Official safety documentation for these preparations does not utilize standard pharmacovigilance terminology and does not document specific serious adverse reactions. In the event of an accidental overdose, the official safety text advises seeking medical attention immediately.

How should Lycopodium be stored and disposed of?

How to Store and Dispose of Lycopodium?

Lycopodium powder (spores) is classified as a flammable solid and requires careful storage and handling. It must be kept in a cool, dry, and well-ventilated area, protected from light, moisture, and high temperatures. Due to the risk of dust explosion, keep the product away from all ignition sources, heat, and open flames, and ensure containers are grounded to prevent static discharge.

For homeopathic liquid forms, store the medication out of reach of children and keep the container tightly closed.

Disposal instructions

Waste material must be disposed of according to national and local regulations. Do not allow the product to enter drains or waterways. For the raw powder, disposal typically requires offering the surplus to a licensed disposal company or incineration in a chemical incinerator equipped with a scrubber due to its high flammability.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Russia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z